格尼迪亚格劳卡 (弗雷森) 的多方面的抗癌潜力 吉尔格叶化物:对多个细胞点的影响
Poorna Vivek Valleti1, Vadlapudi Kumar1, Pradeep Kumar Ramayanam1
1Department of Studies in Biochemistry, Davangere University, Shivagangothri Davangere 577007, Karnataka, India.
ACS omega
|March 4, 2024
概括
格尼迪亚格劳卡 (Gnidia glauca) 的叶子化合物提取物通过向人乳癌细胞中的管聚合,线粒体功能和DNA复制来表现出抗癌性质. 需要进一步的研究来探索其作为植物化学药物候选药物的潜力.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 格尼迪亚格劳卡 (弗雷森语) (Gnidia glauca) 是一种葡萄. 吉尔格通过各种机制具有已知的抗癌潜力.
- 以前的研究表明,它在诱导亡,调节蛋白聚合,维护线粒体功能和抑制DNA聚合酶活动方面具有有效性.
研究的目的:
- 为了研究Gnidia glauca叶子化物提取物的抗癌性质.
- 为了评估提取物对蛋白聚合,DNA聚合酶活性,线粒体膜潜力和人类乳腺癌 (MCF-7) 细胞的亡的影响.
主要方法:
- 从Gnidia glauca的叶子中提取类化合物,使用10%的乙酸在乙醇中.
- 对提取物对管组装,线粒体膜潜力,DNA聚合酶活性和MCF-7细胞中亡诱导的影响的评估.
- 流细胞计用于细胞亡研究和细胞周期分析.
主要成果:
- 叶子化物提取物证明了微管组装的度依赖抑制,这表明螺旋中毒活性.
- 它影响了线粒体膜潜力 (IC50 = 144.51 μg/mL) 并抑制了DNA聚合酶α和β活动,干扰了DNA复制和修复.
- 提取物诱导了DNA损伤 (53.6%),抑制了MCF-7细胞增殖,并在子G0/G1,S和G2/M阶段引起细胞循环停止.
结论:
- 格尼迪亚格劳卡 (Gnidia glauca) 叶子化物提取物含有具有多个细胞标的抗癌化物.
- 这些发现支持Gnidia glauca作为癌症治疗新型植物化学药物候选物的天然来源的潜力.
- 需要进一步的临床前和临床研究来确定疗效,安全性,并确定特定的活性化合物.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Electron Transport Chain: Complex I and II
13.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.3K


